Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct 29:12:370.
doi: 10.1186/1472-6963-12-370.

Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada--a time and motion study

Gayle A Shinder  1 , Pierre Emmanuel Paradis, Marianne Posman, Natalia Mishagina, Marie-Pascale Guay, Dina Linardos, Gerald Batist
Affiliations

Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada--a time and motion study

Gayle A Shinder et al. BMC Health Serv Res. .

Abstract

Background: Mapping patient and work flow and cost analysis studies can help determine the most efficient and cost effective way of providing health services while still maintaining the best standards of care. This study used both time and motion methodology and hospital data to assess the contribution of staff time and facility usage to the overall cost of cancer care during patient visits to a comprehensive cancer centre in Quebec, using metastatic colorectal cancer as a model.

Methods: A workflow diagram was created mapping direct and indirect steps involved during a patient's physician or treatment (FOLFOX/bevacizumab or XELOX/bevacizumab) visit. Staff were timed as they performed each task and this data together with compensation amounts were used to calculate personnel costs. Mean work times and 95% confidence intervals (CI) were calculated. Operation and maintenance (O&M) costs for the Centre were calculated using information from hospital databases. All costs were presented in constant Canadian dollars for the 2010-2011 fiscal year period.

Results: For physician visits, direct and indirect personnel costs were $9.25 (95%CI:$7.00-$11.51) and O&M costs were $60.21, for a total of $69.46 (95%CI:$67.21-$71.72). For treatment visits, personnel and O&M costs were $71.91 (95%CI:$45.53-$98.29) and $62.00 respectively for a total of $133.91 (95%CI:$107.53-$160.29). When calculated for treatment alone, the total cost was $136.06 (95%CI:$109.16-$162.95) for FOLFOX/bevacizumab and $119.94 (95%CI:$96.89-$142.99) for XELOX/bevacizumab. The highest cumulative personnel costs were for the pharmacists and nurses ($38.87 and $34.82 respectively). Regarding patient flow, total time in between steps was 77.6 and 49.5 minutes for a physician or treatment visit respectively.

Conclusions: This study from a health care provider's perspective, demonstrated that in the context of increasingly expensive therapies, costs associated with staff time and facility usage do not contribute greatly to the overall cost of treating cancer at this cancer centre. It also illustrated the need for improvements in patient and work flow to reduce wait times in the clinic.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Workflow Diagram – Physician and Treatment Visits.
See this image and copyright information in PMC

References

    1. Canadian Partnership Against Cancer. The Future of Cancer Control in Canada. A discussion paper on pan-Canadian cancer control priorities for 2012–2017. Toronto, ON: CPAC; 2011.
    1. Bending MW, Trueman P, Lowson KV, Pilgrim H, Tappenden P, Chilcott J, Tappenden J. Estimating the direct costs of bowel cancer services provided by the National Health Service in England. Int J Technol Assess Health Care. 2010;26(4):362–369. doi: 10.1017/S0266462310001078. - DOI - PubMed
    1. Cromwell I, van der Hoek K, Melosky B, Peacock S. Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real world cost effectiveness analysis. J Thorac Oncol. 2011;6(12):2097–2103. doi: 10.1097/JTO.0b013e31822f657a. - DOI - PubMed
    1. Mittmann N, Au H-J, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ. Working Group on Economic Analysis of the National Cancer Institute of Canada Clinical Trials Group, Australasian Gastrointestinal Interest Group. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaulation of national cancer institute of canada clinical trials group, CO.17 Trial. J Natl Cancer Inst. 2009;101(17):1182–1192. doi: 10.1093/jnci/djp232. - DOI - PubMed
    1. Cassidy J, Douillard J-Y, Twelves C, McKendrick JJ, Scheithauer W, Bustová I, Johnston PG, Lesniewski-Kmak K, Jelic S, Fountzilas G, Coxon F, Díaz-Rubio E, Maughan TS, Malzyner A, Bertetto O, Beham A, Figer A, Dufour P, Patel KK, Cowell W, Garrison LP. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: the X-ACT trial. Br J Cancer. 2006;94:1122–1129. doi: 10.1038/sj.bjc.6603059. - DOI - PMC - PubMed

Publication types